VFA
ARKG icon

Valeo Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Valeo Financial Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,867
Closed -$450K – 587
2021
Q2 		$450K Buy
4,867
+2,800
+135% +$238K 0.03% 280
2021
Q1 		$183K Sell
2,067
-1,665
-45% -$165K 0.01% 465
2020
Q4 		$348K Buy
3,732
+3,723
+41,367% +$297K 0.02% 302
2020
Q3 		$1K Buy
+9
New +$527 ﹤0.01% 1462

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Valeo Financial Advisors's ARKG Position: Q3 2021 in Review

Valeo Financial Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 4,867 shares — an estimated $450K sold.

Valeo Financial Advisors first reported a position in ARKG in Q3 2020 and held it in 4 quarters. The position peaked at $450K in Q2 2021. 470 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

  • Valeo Financial Advisors reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 4,867 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $450K.
  • Valeo Financial Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 4 quarters.
  • Valeo Financial Advisors's ARK Genomic Revolution ETF position peaked at $450K in Q2 2021.
  • 470 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on Valeo Financial Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.